Enliven Therapeutics Cash Flow Statement
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
40.98+0.35 (+0.86%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics free cash flow
In fiscal 2025, Enliven Therapeutics generated -$70.3 million of operating cash flow and spent $158,000 on capital expenditures. That left free cash flow of -$70.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -103.69M | -89.02M | -71.58M | -37.66M | -51.38M | -41.36M | -23.46M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 300.00K | 300.00K | 300.00K | 200.00K | 99.00K | 97.00K | 33.00K |
| Stock-Based Compensation | 34.02M | 20.17M | 12.91M | 3.19M | 3.85M | 2.23M | 899.00K |
| Change in Working Capital | 817.00K | 810.00K | -2.25M | 411.00K | 389.00K | 253.00K | 662.00K |
| Operating Cash Flow | -70.30M | -73.19M | -61.27M | -32.08M | -46.77M | -37.40M | -21.88M |
| Capital Expenditures | -158.00K | -44.00K | -149.00K | -612.00K | -12.00K | -18.00K | -140.00K |
| Investing Cash Flow | -173.84M | -36.00M | -148.41M | -612.00K | -1.63M | -16.72M | -24.06M |
| Financing Cash Flow | 218.87M | 133.16M | 234.29M | -1.80M | 49.10M | 96.88M | 43.58M |
| Net Change in Cash | -25.27M | 23.98M | 24.61M | -34.49M | 698.00K | 42.76M | -2.36M |
| Free Cash Flow | -70.46M | -73.24M | -61.42M | -32.69M | -46.78M | -37.42M | -22.02M |
This table shows 7 annual periods of Enliven Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a cash flow statement?